Exploring Hybrid Nanoparticles for Crizotinib Delivery in Lung Cancer Treatment; Design, Optimization, In-vitro and Cell Line Evaluation

Key Points

• Crizotinib delivery improves when utilizing hybrid nanoparticles for lung cancer treatment and shows promising in-vitro results.
• The study evaluates the effectiveness through in-vitro experiments on multiple cell lines, yielding a significant enhancement in drug delivery mechanisms.
• Observational analysis details the design and optimization of hybrid nanoparticles for targeted treatment of lung cancer.
• This approach may lead to more effective therapies for lung cancer, highlighting the need for advanced delivery systems.